JCAR 023 / BMS, Fred Hutchinson Cancer Center - LARVOL DELTA

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 (clinicaltrials.gov) - P1; N=65; Active, not recruiting; Sponsor: Seattle Children's Hospital; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Ganglioneuroblastoma • Neuroblastoma • Oncology • Solid Tumor

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 (clinicaltrials.gov) - P1; N=65; Recruiting; Sponsor: Seattle Children's Hospital; N=40 ➔ 65; Trial completion date: Nov 2037 ➔ Nov 2038; Trial primary completion date: Nov 2022 ➔ Nov 2023

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Ganglioneuroblastoma • Neuroblastoma • Oncology • Solid Tumor

"@DrPaulyDeSantis @dan_smithey $JUNO catalysts updated" - dough, @tgtxdough

Anticipated P1 data • Anticipated P1/2 data • Tweet • Hematological Malignancies • Oncology